The Oregon Clinical & Translational Research Institute (OCTRI) is now accepting letters of intent to apply for its Biomedical Innovation Program. The program cultivates and selects promising translational projects that develop new biomedical devices, diagnostics, and software with the objective of moving innovative technologies to clinical application, making a meaningful impact on human health.
Deadline: Letters of intent due Nov. 12, 2014
Amount: Up to $40,000 over one year
Eligibility: Principal investigators must fit OHSU eligibility requirements.
Critical elements of successful proposals will be a well-developed idea or vision for the end product and a collaboration between clinicians, scientists, and bioengineers. That collaboration will make possible the identification of a significant clinical problem, an innovative idea for a device or diagnostic to address the problem, bioengineering approaches for device or diagnostic development, voice of consumer studies, and early clinical trials.
Learn more about this and other OCTRI funding opportunities.
In response to a growing interest in research strategies for the early detection of cancers, Dr. Joe Gray of the Center for Spatial Systems Biomedicine, Dr. R. Stephen Lloyd of the Oregon Institute of Occupational Health Sciences and Dr. Brian Druker of the Knight Cancer Institute are hosting a symposium titled Genomic Instability and Cancer: Early Detection and Novel Therapeutics. The main topic will be early detection of cancer using genomic instability as a marker.
Speakers include Alan Ashworth of UCSF, Arthur Grollman of SUNY Stony Brook, Rick Wood of M.D. Anderson Cancer Center, Rosana Risques of the University of Washington, and a number of OHSU faculty.
The symposium will run all day Friday, Oct. 24, beginning at 8:30 a.m. in the Old Library Auditorium. Food and beverage will be provided throughout the day, with a wine and appetizer reception after the final talk. Registration is free.
The U.S. Army Medical Research and Materiel Command has a new funding opportunity available: the Extramural Medical Research program. This program must be for basic and applied research and must be for scientific study and experimentation directed toward advancing the state-of-the-art or increasing knowledge and understanding rather than focusing on a specific system or hardware solution. Research and development funded through this program are intended and expected to benefit and inform both military and civilian medical practice and knowledge.
The research program areas are:
- Military Infectious Diseases – Focuses on vaccines, anti-parasitic drugs, deployable field clinical diagnostics (human and vector), prophylactics and novel therapeutics to treat multidrug-resistant organisms in combat wound infections, as well as vector control pertinent to naturally occurring endemic diseases with demonstrated or potential capability to decrease military operational effectiveness.
- Combat Casualty Care – Provides integrated capabilities for far-forward medical care to reduce the mortality and morbidity associated with major combat-related trauma across the spectrum of combat casualty care including point-of-injury and pre- or out-of-hospital care, the spectrum of en-route care, and facilities-based treatment.
- Military Operational Medicine – Conducts biomedical research to deliver products and solutions to the Service member that address health and fitness throughout the deployment cycle. The program is centered on cutting-edge scientific research and bringing science to the Service member on the battlefield in a relevant, timely manner.
- Clinical and Rehabilitative Medicine – Focuses on the innovations required to reset our wounded Service members, both in terms of duty performance and quality of life.
- Medical Biological Defense – Provides medical countermeasures for biological warfare agents.
- Medical Chemical Defense – Seeks to preserve combat effectiveness by timely provision of medical countermeasures in response to Joint Service chemical warfare defense requirements.
- Medical Simulation and Information Sciences – The mission of this program is to explore the implications of models and technology for medical education and for the provision, management and support of health services in the military.
- Radiation Health Effects – Focuses on developing medical countermeasures for acute ionizing radiation injury.
- Special Investment Areas/Innovation Funding – Seeking new and innovative science that promises benefit to military health and medicine.
Awards are made to organizations only. Eligible investigators include all individuals, regardless of ethnicity, nationality, or citizenship status, who are employed by, or affiliated with, an eligible organization. A specific amount of funding has NOT been set aside for this Announcement, and the number of awards is indeterminate and contingent upon funding availability. The total period of performance may be up to five years, except for the “Special Investment Areas/Innovation Funding” area of interest. Those projects are generally 18 months or less in duration and limited to $500,000 total.
Pre-proposal deadline: September 30, 2015
Please Join Us for the 2014 Portland Series Launch:
What Can Your Genes Tell You?
Value, validity and implications of direct to consumer genetic testing for personal health data. Co-facilitated by Summer Cox, MPH and Shaban Demirel, PhD.
October 21, 2014 5:45 – 7:30 p.m.
The Lucky Labrador Pub (all ages)
915 SE Hawthorne Blvd., Portland, OR 97214
$5 General Admission
Includes discussion and first glass of wine/beer if 21+
REGISTER at http://www.nwabr.org/communityconversation/portland
What are Community Conversations?
Each informal Conversation explores a topic in biomedical science and its relationship with ethics, medicine, research and society, connecting people to the biomedical research community. Learning from each other, our goal is to help people thoughtfully engage in and advance biomedical research. Everyone is welcome. No science background necessary.
In partnership with NWABR members Oregon Health & Science University and Portland State University and supporters Legacy Research Institute and Oregon Health Authority
Did you know that the NIH Common Fund was holding a video competition to commemorate its 10-year anniversary? Neither did we, but after seeing this Common Fund rap, we will definitely be going with the Common Fund.
A laboratory notebook is critical to document research that may form the basis of a patentable invention. An accurate record can show who made the invention, the contributions of each inventor, and how the invention was made. Senior Technology Development Manager Michele Gunness will lead this seminar to present updates on patent law and best practices to maintain your laboratory notebook to assist your attorney when preparing a patent application and providing support to your invention.
This event is open to all OHSU employees, faculty and students. Admission is free and no RSVP is necessary. The event will be catered by Ingallina’s Box Lunch. Lunches will be provided on a first-come, first-served basis.
Tuesday, October 21, 2014
Marquam Hill Campus, Mackenzie Hall 2201
For questions or concerns, please contact Karen Ho.
The unrestricted $500,000 prize is presented to a leading scientist, or group of scientists (up to three), in recognition of groundbreaking contributions to any realm of genetics research. These contributions may include original discoveries in genetic function, regulation, transmission, and variation, as well as in genomic organization. Nominations may be submitted by individuals, organizations, and institutions that are active in or have an appreciation for contemporary genetic research or problems.
This unrestricted cash award of $500,000 is awarded each year to a person or persons chosen by a distinguished advisory board of neuroscience experts from nominations that are received from around the world. Nominations for this prize are invited annually and may be submitted by individuals, organizations, and institutions that are active in or have an appreciation for contemporary neuroscience research and study. Individuals from anywhere in the world who have conducted highly distinguished research in the field of the brain, spinal cord, or peripheral nervous system may be nominated.
The nomination deadline for both the Neuroscience and Genetics Prizes is December 15, 2014.
On Monday, October 6, Technology Transfer and Business Development (TTBD) hosted the 2014 TTBD Awards to recognize OHSU researchers who had technologies licensed or optioned in the last fiscal year as well as those who brought in top dollars from industry to support their research. The ceremony drew an enthusiastic crowd to the Portland State University lecture hall at the new Collaborative Life Sciences Building.
We’d like to congratulate all of the researchers who were recognized at this year’s Innovation Awards ceremony, including:
Dr. Vandenbark is a Professor of MMI and Neurology at OHSU and a Senior Research Career Scientist at the VAMC. He is the Co-Director of the Neuroimmunology Program that is focused on the development and translation of novel therapeutic immunoregulatory and neuroprotective agents for treatment of multiple sclerosis and other autoimmune and inflammatory diseases of the central nervous system. Since 1999, Dr. Vandenbark has disclosed 27 new inventions to Technology Transfer, 11 of which are exclusively licensed. He is also an inventor on 15 issued US patents and has collaborated with industry on several research studies.
Dr. Hutchens serves as Associate Professor in the Department of Anesthesiology & Perioperative Medicine and is a critical care physician in the Knight Cardiovascular Intensive Care Unit. Dr. Hutchens is the recipient of a NIDDK-funded K08 grant for his research focusing on sex and acute kidney injury. Dr. Hutchens is also the recipient of an OHSU Biomedical Innovation Program Award. OHSU has filed patents on two of Dr. Hutchens’ nine disclosed inventions, one of which is exclusively optioned to a company for evaluation. Dr. Hutchens’ inventions thus far focus on bringing smart, reliable technology to the patient as wearable or bedside devices to improve safety.
Business Partnership Achievement Award: Sanjiv Kaul, M.D.
Dr. Kaul is currently the Ernest C. Swigert Chair of Cardiovascular Medicine, Professor of Medicine and Radiology, CEO of the Knight Cardiovascular Institute and Associate Dean, School of Medicine at OHSU. His major clinical and research interest is coronary artery disease. He is a pioneer in cardiovascular imaging, having spearheaded many of the developments in contrast echocardiography and making major contributions to the field of nuclear cardiology.
TTBD also recognized the hard work of the OHSU Office of Proposal and Award Management with an award of appreciation.
The winning image
Dr. Peter Barr-Gillespie, Ph.D, and Kateri Spinelli, Ph.D. are one of 12 winners of the 2014 Federation of American Societies for Experimental Biology (FASEB) annual BioArt competition. Their submission, showing the sensory hair cells of a chick, was captured by scanning electron microscopy. The image comes from joint work to discover better methods to detect and treat hearing loss and disrupted balance.
The 12 winning images and videos demonstrate the breadth of ongoing research in the biomedical and life sciences. Winning entries were unveiled on FASEB’s website and will be exhibited at the National Institutes of Health. The BioArt competition is open to members of FASEB constituent societies and biomedical and life scientists whose research is supported by federal funds. More information about the competition can be found on the BioArt website.
The American Heart Association has announced its winter deadlines for a wide range of funding opportunities relating to cardiovascular disease and stroke. All proposals and applications will be due either January 15th or 22nd, 2015.
American Heart Association – Winter 2015 Funding Opportunities
- Pre-Doctoral Fellowship – $25,000 per year for one or two years to help students begin careers in cardiovascular or stroke related research by providing research assistance and training. Research should be broadly related to cardiovascular function and disease and stroke, or to related clinical, basic science, bioengineering or biotechnology, and public health problems, including multidisciplinary efforts.
- Postdoctoral Fellowship – $40,000-$50,000 per year for up to two years. This opportunity is intended to help trainees initiate careers in cardiovascular and stroke research while obtaining significant research results under the supervision of a sponsor or mentor; supports individuals before they are ready for some stage of independent research.
- Beginning Grant-in-Aid – Up to $70,000 per year for up to two years to promote the independent status of promising beginning scientists. Research should be broadly related to cardiovascular function and disease and stroke, or related clinical, basic science, bioengineering or biotechnology, and public health problems, including multidisciplinary efforts.
- Grant-in-Aid – Up to $70,000 per year for up to two years to fund the most innovative and meritorious research projects from independent investigators. Research must be broadly related to cardiovascular function and disease and stroke, or to clinical, basic science, bioengineering or biotechnology, and public health problems.
- Mentored Clinical and Population Research Award – Up to $75,000 per year for up to two years to encourage early investigators who have appropriate and supportive mentoring relationships to engage in high quality introductory and pilot clinical studies that will guide future strategies for reducing cardiovascular disease and stroke while fostering new research in clinical and translational science, and encouraging community and population-based activities.
- National Scientist Development Grant – Up to $77,000 per year for up to four years to support beginning scientists in their progress toward independence by funding research projects that can bridge the gap between completion of research training and readiness for a successful career as an independent investigator.
View the rest of this weeks Funding Alerts.